An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Epimmune

Status and phase

Completed

Phase 1

Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasm

Treatments

Biological: EP2101

Study type

Interventional

Funder types

Industry

Identifiers

NCT00054899

EP2101-101

Details and patient eligibility

About

EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Non-Small Cell Lung Cancer.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of Non-Small Cell Lung Cancer, stage IIb or IIIa
At least four weeks following prior standard treatment, with no evidence of disease
Must use adequate birth control

Exclusion criteria

Prior cancer vaccine therapy or concurrent participation in any other investigational study
A history of HIV, Hepatitis B or C, or any other acute medical condition which may compromise patient safety or the activity of the study vaccine treatment
A history of adverse reactions following administration of any vaccines, or a history of hypersensitivity to any components of the study vaccine
Women who are pregnant, intend to become pregnant, or who are breast feeding